CheckMate 647: A Phase 2, open-label study of nivolumab in relapsed/refractory primary central nervous system lymphoma or relapsed/refractory primary testicular lymphoma Meeting Abstract
| Authors: | Nayak, L.; Iwamoto, F. M.; Ferreri, A. J.; Santoro, A.; Singer, S.; Batlevi, C.; Batchelor, T.; Rubenstein, J.; Johnston, P.; Ramchandren, R.; Soussain, C.; Drappatz, J.; Becker, K.; Witzens-Harig, M.; Illerhaus, G.; Herrera, A.; Masood, A.; Shipp, M. |
| Abstract Title: | CheckMate 647: A Phase 2, open-label study of nivolumab in relapsed/refractory primary central nervous system lymphoma or relapsed/refractory primary testicular lymphoma |
| Meeting Title: | 14th International Conference on Malignant Lymphoma |
| Journal Title: | Hematological Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2017 Jun 14-17 |
| Meeting Location: | Lugano, Switzerland |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2017-06-07 |
| Start Page: | 420 |
| End Page: | 421 |
| Language: | English |
| ACCESSION: | 123459679 |
| DOI: | 10.1002/hon.2440_2 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cin20 |
| DOI/URL: | |
| Notes: | Meeting Abstract: OT03 -- Accession Number: 123459679 -- Entry Date: In Process -- Revision Date: 20170608 -- Publication Type: Article -- Supplement Title: Jun2017 Supplement -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 8307268. -- Source: cin20 |
